« Back
Home /
VT02956

VT02956

Item no.	HY-147165-25mg
Manufacturer	MedChem Express
CASRN	2999763-09-4
Amount	25 mg
Quantity options	10 mg 1 ea 25 mg 50 mg 5 mg
Category	Reagents & Chemicals Other Chemicals
Type	Reagents
Specific against	other
Purity	99.58
Formula	C22H23N5O
Citations	[1]Ma S, et al. Transcriptional repression of estrogen receptor alpha by YAP reveals the Hippo pathway as therapeutic target for ER+ breast cancer. Nat Commun. 2022 Feb 25;13(1):1061.
Smiles	NCC1CCN(CC1)C2=NC(C3=CC=NC=C3)=NC4=C2C=CC=C4C#CCO
ECLASS 10.1	42051003
ECLASS 11.0	42051003
UNSPSC	12000000
Available
Product Description	VT02956 is a LATS inhibitor (IC50: 0.76 nM for LATS1, 0.52 nM for LATS2). VT02956 targets the Hippo pathway. VT02956 inhibits ESR1 expression and growth of ER+ breast cancer cell lines and patient-derived tumor organoids[1]. VT02956 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
StorageTemperature	-20°C, 3 years; 4°C, 2 years (Powder)
Shipping	Room Temperature
Manufacturers Applications	Cancer-Kinase/protease
MolecularWeight	373.45
Clinical Information	No Development Reported
Manufacturers Research Area	Cancer
Solubility	DMSO : 100 mg/mL (ultrasonic)
Target	YAP
Manufacturers Target	YAP
Manufacturers Pathway	Stem Cell/Wnt
Manufacturers Product type	Reference compound

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

Request safety datasheet

Simple Order Order Subscription

Amount: 25 mg

available

Request delivery time